vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) reported Q1 2026 revenue of $36.8 million and net income attributable to shareholders of $24.1 million, or $1.94 basic and $1.65 diluted EPS.
Cash and equivalents were $98.1 million, supported by a $20 million upfront payment from a Newsoara license amendment. Phase 3 CATT1 enrollment for cadisegliatin in type 1 diabetes remains on track to complete in Q3 2026, with cash expected to fund operations through topline data.
Positive
- Q1 2026 revenue of $36.8 million versus no revenue in Q1 2025
- Q1 2026 net income of $24.1 million versus prior-year net loss
- Cash and cash equivalents of $98.1 million at March 31, 2026
- $20 million upfront cash from amended Newsoara HPP737 license plus potential milestones and royalties
- Phase 3 CATT1 enrollment for cadisegliatin expected to complete in Q3 2026
- Company expects cash to fund operations through anticipated CATT1 topline data readout
Negative
- Research and development expenses rose to $9.0 million from $2.8 million year over year
- General and administrative expenses increased to $4.6 million from $3.7 million year over year
News Market Reaction – VTVT
In the May 14 session, VTVT gained 21.36%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.0% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Q4/FY 2025 earnings | Positive | +0.2% | Reported FY 2025 results, $88.9M cash and $20M Newsoara upfront with CATT1 progress. |
| Nov 06 | Q3 2025 earnings | Positive | +2.2% | Q3 2025 results, first CATT1 randomization, $80M private placement and cash at $98.5M. |
| Aug 12 | Q2 2025 earnings | Neutral | -3.2% | Q2 2025 loss with higher R&D and lower cash while advancing CATT1 and IP. |
| May 15 | Q1 2025 earnings | Negative | -6.2% | Q1 2025 loss, declining cash and higher R&D as CATT1 screening resumed. |
| Mar 20 | FY 2024 earnings | Positive | -5.5% | FY 2024 results with clinical hold lifted and plans to resume CATT1 in Q2 2025. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and financial updates have historically produced modest, often negative or mixed next-day moves, even when updates advanced the CATT1 program or strengthened the balance sheet.
Over the last several earnings cycles, vTv has repeatedly linked financial updates to progress in its Phase 3 CATT1 program and balance sheet strengthening. Prior releases highlighted resumed CATT1 enrollment after an FDA hold, protocol changes shortening trial duration, first patient randomization, and an $80 million private placement that lifted cash to $98.5 million by Q3 2025. Despite these developments, typical 24-hour moves around earnings averaged about -2.48%, indicating historically muted or cautious trading versus generally constructive operational progress.
Key Terms
phase 3 medical
adjunctive therapy medical
pde4 inhibitor medical
tiered royalties financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026
Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout
HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cash currently on hand.
“We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders.”
Recent Company Highlights
- Phase 3 CATT1 Trial Progressing: Enrollment is ongoing in the Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D. The Company expects to complete enrollment in the third quarter of 2026, supported by expanded site activation and increased investigator and patient engagement.
- License Amendment Adds Non-Dilutive Capital: In February 2026, the Company announced an amendment to its license agreement with Newsoara Biopharma, granting Newsoara global rights to the Company's highly selective PDE4 inhibitor, HPP737. Under the amended agreement, the Company received a
$20.0 million upfront payment and is eligible to receive up to approximately$50.0 million in development milestones, up to$65.0 million in sales milestones, and tiered royalties on net sales. The transaction strengthens the Company's balance sheet and maintains strategic focus on advancing cadisegliatin.
First Quarter 2026 Financial Results
- Cash Position: Cash and cash equivalents as of March 31, 2026, were
$98.1 million , compared to$88.9 million as of December 31, 2025. The increase reflects the$20.0 million upfront payment received under the recent amendment to the Newsoara license, partially offset by operating expenditures. - Research & Development (R&D) Expenses: R&D expenses were
$9.0 million and$2.8 million in each of the three months ended March 31, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial. - General & Administrative (G&A) Expenses: G&A expenses were
$4.6 million and$3.7 million for each of the three months ended March 31, 2026, and 2025, respectively. The increase reflects ongoing support for corporate operations and clinical development activities. - Interest Income: Interest income for the three months ended March 31, 2026, and 2025, of
$0.8 million and$0.3 million , respectively, is related to dividend income from our money market accounts. - Net Income (Loss): Net income attributable to vTv shareholders for the three months ended March 31, 2026, was
$24.1 million or$1.94 and$1.65 per basic and diluted share, respectively. Net loss attributable to vTv shareholders for the comparable period a year ago was$5.1 million or$0.77 per basic and diluted share.
Upcoming Events
- H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Tuesday, May 19, 2026
Time: 12:30 PM ET
Location: New York, NY
Webcast Link - Alliance Global Partners Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 20, 2026
Time: 4:20 PM ET
Location: Virtual
Event Webcast Link
| vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands) | |||||||
| March 31, 2026 | December 31, 2025 | ||||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 98,086 | $ | 88,932 | |||
| Prepaid expenses | 521 | 743 | |||||
| Other current assets | 201 | 218 | |||||
| Total current assets | 98,808 | 89,893 | |||||
| Other assets | 5 | 6 | |||||
| Total assets | $ | 98,813 | $ | 89,899 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 6,821 | $ | 6,557 | |||
| Warrant liability, related party | 60 | 84 | |||||
| Total current liabilities | 6,881 | 6,641 | |||||
| Contract liabilities | 1,830 | 18,669 | |||||
| Warrant liability | 143 | 152 | |||||
| Total liabilities | 8,854 | 25,462 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Class A Common Stock | 39 | 39 | |||||
| Class B Common Stock | — | — | |||||
| Additional paid-in capital | 392,478 | 391,090 | |||||
| Accumulated deficit | (302,558 | ) | (326,692 | ) | |||
| Total stockholders’ equity | 89,959 | 64,437 | |||||
| Total liabilities and stockholders’ equity | $ | 98,813 | $ | 89,899 | |||
| vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| (Unaudited) | |||||||
| Revenue | $ | 36,839 | $ | — | |||
| Operating expenses: | |||||||
| Research and development | 8,978 | 2,830 | |||||
| General and administrative | 4,598 | 3,673 | |||||
| Total operating expenses | 13,576 | 6,503 | |||||
| Operating income/(loss) | 23,263 | (6,503 | ) | ||||
| Interest income | 838 | 331 | |||||
| Other income (expense), net | 33 | (45 | ) | ||||
| Net income (loss) before income taxes and noncontrolling interest | 24,134 | (6,217 | ) | ||||
| Income tax provision | — | — | |||||
| Net income (loss) before noncontrolling interest | 24,134 | (6,217 | ) | ||||
| Less: net loss attributable to noncontrolling interest | — | (1,125 | ) | ||||
| Net income (loss) attributable to vTv Therapeutics Inc. | $ | 24,134 | $ | (5,092 | ) | ||
| Net income (loss) attributable to vTv Therapeutics Inc. common shareholders | $ | 24,134 | $ | (5,092 | ) | ||
| Basic net income (loss) per share of vTv Therapeutics Inc. Class A common stock | $ | 1.94 | $ | (0.77 | ) | ||
| Basic weighted average number of vTv Therapeutics Inc. Class A common stock | 12,409,278 | 6,582,844 | |||||
| Diluted net income (loss) per share of vTv Therapeutics Inc. Class A common stock | $ | 1.65 | $ | (0.77 | ) | ||
| Diluted weighted average number of vTv Therapeutics Inc. Class A common stock | 14,634,420 | 6,582,844 | |||||
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
